About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into a licensing and supply agreement with CRISTÁLIA, one of the leading pharmaceutical companies in Brazil, for the commercialization of ADL-018 / bOmalizumab, a proposed biosimilar to Xolair®, in Latin America (LATAM). In 2024, IQVIA recorded approximately $5.0 billion in global sales, with approximately $140 million contributed by the LATAM region.

Under the terms of the agreement, Kashiv BioSciences is responsible for the development of the product within the agreed territories. CRISTÁLIA will be responsible for the licensing, distribution, and commercialization of ADL-018 in the LATAM region.

Dr. Sandeep Athalye, Chief Executive Officer at Kashiv BioSciences said, “CRISTÁLIA is an ideal partner to commercialize ADL-018 across Latin America, supporting Kashiv’s mission to expand its biosimilar portfolio and increase global access. We look forward to CRISTÁLIA bringing our omalizumab biosimilar to patients in this important region.”

“We are thrilled to have entered a partnership with Kashiv for the licensing of Omalizumab biosimilars in the LATAM region,” Dr. Ogari Castro Pacheco, Chairman of CRISTÁLIA stated, “CRISTÁLIA is confident that this molecule will be a key asset to our biosimilars portfolio and as part of our company strategy to expand patient access to high quality, affordable treatments in the future.”

About ADL-018:

ADL-018 is a proposed Xolair® biosimilar. Omalizumab is a humanized monoclonal antibody that targets free immunoglobulinE (IgE). Xolair® is indicated for the treatment of Chronic Idiopathic Urticaria (CIU) or Chronic Spontaneous Urticaria (CSU), severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy. ADL-018 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.

Xolair® is a registered trademark of Genentech, Inc. and Novartis AG.

About Kashiv BioSciences

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with a robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.

For more information, please visit https://www.kashivbiosciences.com/

About CRISTÁLIA

CRISTÁLIA is a private owned Brazilian biopharma company, with 53 years of operation and a broad footprint across the main Latin America markets. CRISTÁLIA is dedicated to the discovery, development, manufacturing, and commercialization of life-saving treatments to patients with severe, life-threatening diseases or injuries.

In addition to the biopharmaceutical business, CRISTÁLIA also ranks between the biggest API manufacturers in Latin America, with state-of-the-art facilities dedicated to the manufacturing of synthetic, oncologic and biotech active ingredients.

CRISTÁLIA is headquartered in Campinas (Brazil).

For more information, please visit Cristália - Indústria Farmacêutica

Dr. Sandeep Athalye, Chief Executive Officer at Kashiv BioSciences said, “CRISTÁLIA is an ideal partner to commercialize ADL-018 across Latin America, supporting Kashiv’s mission to expand its biosimilar portfolio and increase global access."

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.